NASDAQ:CGON - Nasdaq - US1569441009 - Common Stock - Currency: USD
26.22
-0.34 (-1.28%)
The current stock price of CGON is 26.22 USD. In the past month the price increased by 26.48%. In the past year, price decreased by -19.84%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.7 | 321.60B | ||
AMGN | AMGEN INC | 13.07 | 145.89B | ||
GILD | GILEAD SCIENCES INC | 13.92 | 134.11B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.91B | ||
REGN | REGENERON PHARMACEUTICALS | 13.65 | 65.28B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.06B | ||
ARGX | ARGENX SE - ADR | 99.65 | 35.72B | ||
ONC | BEIGENE LTD-ADR | 5.89 | 25.49B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
NTRA | NATERA INC | N/A | 20.54B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.87B | ||
BIIB | BIOGEN INC | 8.02 | 18.58B |
CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. The company is headquartered in Irvine, California and currently employs 113 full-time employees. The company went IPO on 2024-01-25. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
CG ONCOLOGY INC
400 Spectrum Center Drive, Suite 2040
Irvine CALIFORNIA US
Employees: 61
Phone: 19492886298
The current stock price of CGON is 26.22 USD. The price decreased by -1.28% in the last trading session.
The exchange symbol of CG ONCOLOGY INC is CGON and it is listed on the Nasdaq exchange.
CGON stock is listed on the Nasdaq exchange.
15 analysts have analysed CGON and the average price target is 63.88 USD. This implies a price increase of 143.62% is expected in the next year compared to the current price of 26.22. Check the CG ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CG ONCOLOGY INC (CGON) has a market capitalization of 2.00B USD. This makes CGON a Small Cap stock.
CG ONCOLOGY INC (CGON) currently has 61 employees.
CG ONCOLOGY INC (CGON) has a support level at 25.27 and a resistance level at 27.74. Check the full technical report for a detailed analysis of CGON support and resistance levels.
The Revenue of CG ONCOLOGY INC (CGON) is expected to decline by -10.89% in the next year. Check the estimates tab for more information on the CGON EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CGON does not pay a dividend.
CG ONCOLOGY INC (CGON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.51).
The outstanding short interest for CG ONCOLOGY INC (CGON) is 17.01% of its float. Check the ownership tab for more information on the CGON short interest.
ChartMill assigns a technical rating of 4 / 10 to CGON. When comparing the yearly performance of all stocks, CGON is a bad performer in the overall market: 74.22% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to CGON. No worries on liquidiy or solvency for CGON as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months CGON reported a non-GAAP Earnings per Share(EPS) of -1.51. The EPS decreased by -31.9% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -11.66% | ||
ROE | -12% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 81% to CGON. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -29.51% and a revenue growth -10.89% for CGON